Gemer 3 Tablet PR is a combination oral hypoglycemic agent containing Glimepiride 3mg and Metformin 500mg, indicated for the management of type 2 diabetes mellitus. Glimepiride, a sulfonylurea class drug, stimulates pancreatic beta cells to increase insulin secretion, thereby reducing blood glucose levels. Metformin, a biguanide, improves insulin sensitivity by decreasing hepatic glucose production and enhancing peripheral glucose uptake and utilization. The combination provides complementary mechanisms of action, offering improved glycemic control in patients inadequately controlled by diet, exercise, and monotherapy. Gemer 3 Tablet PR is typically prescribed as part of a comprehensive diabetes management plan including lifestyle modifications such as diet and physical activity. It is contraindicated in patients with type 1 diabetes, diabetic ketoacidosis, severe renal or hepatic impairment, and conditions predisposing to hypoxia. Common adverse effects may include gastrointestinal disturbances such as nausea, vomiting, diarrhea, and rarely hypoglycemia due to glimepiride. Regular monitoring of blood glucose levels, renal function, and periodic assessment of hematologic parameters are recommended during therapy. Dose adjustments should be individualized based on therapeutic response and tolerability. Patients should be advised to adhere to prescribed dosing schedules and report any signs of hypoglycemia or lactic acidosis promptly.